Updated on 28 July 2026
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
CEO at Shanghai Haiju Biotechnology Co., Ltd.
China
About
HJ-462 features protein kinase inhibitors with ingenious molecular designs that avoid defects in drug metabolism within the body, resulting in excellent safety and remarkable efficacy(achieving 100% tumor regression in liver cancer, gastric cancer, and lung cancer models caused by MET amplification, effectively curing these conditions).
Project Location
- China
Project Format
- Private Project
Go Global Project
- Yes
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Investment / Financing Discussion
Main Project Sector
- Technology
Technology
- Bio-Tech
- Health Technology
Total Project Value
- 5,000,001 to 7,500,000 USD
Investment Capital Required
- 1,000,001 to 2,500,000 USD
Interested Format of Cooperation
- Convertible Loan
- Direct Equity Investment
- Joint Venture
- M&A / Strategic Acquisition Opportunity
Preferred Financing Model
- Debt
- Equity
Type(s) of Last Financing Round of the project (if Applicable)
- Equity (private)
Main Service(s) Required
- Financial Services
Attached files
Organisation
Similar opportunities
Project
Point-of-care Early Cancer Breath Testing
- No
- Yes
- Debt
- Equity
- Technology
- Private Project
- Health Technology
- Convertible Loan
- Equity (private)
- Medical Technology
- Financial Services
- Open for negotiation
- Open for Negotiation
- Minority Shareholdings
- Direct Equity Investment
- Institutional Investment
- 2,500,001 to 5,000,000 USD
- Public / Alternative Financing
- Private Equity & Venture Capital
- Investment / Financing Discussion
Grover Cheung
Founder & CEO at Qi Diagnostics Limited
China (Hong Kong)
Project
- Yes
- Yes
- Equity
- Bio-Tech
- Technology
- Operations
- Private Project
- Convertible Loan
- Health Technology
- Convertible Loan
- Medical Technology
- Financial Services
- Open for negotiation
- Direct Equity Investment
- Institutional Investment
- 2,500,001 to 5,000,000 USD
- 10,000,001 to 25,000,000 USD
- M&A / Strategic Acquisition Opportunity
Enrico Di Oto
CEO at OACP IE LTD
Italy
Project
A First-in-Class Antivirulence Drug for the Treatment of Eczema (Atopic Dermatitis)
- No
- Yes
- Equity
- Bio-Tech
- Technology
- Private Project
- Equity (private)
- Professional Services
- Minority Shareholdings
- 50,000,001 USD or above
- Direct Equity Investment
- 5,000,001 to 7,500,000 USD
- Risk Management & Resilience
- Private Equity & Venture Capital
- Investment / Financing Discussion
Thomas Lee
Chief Operating Officer at Antenovus Biotechnology Limited
China (Hong Kong)